326 related articles for article (PubMed ID: 29309612)
1. Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.
Audrito V; Managò A; La Vecchia S; Zamporlini F; Vitale N; Baroni G; Cignetto S; Serra S; Bologna C; Stingi A; Arruga F; Vaisitti T; Massi D; Mandalà M; Raffaelli N; Deaglio S
J Natl Cancer Inst; 2018 Mar; 110(3):. PubMed ID: 29309612
[TBL] [Abstract][Full Text] [Related]
2. Tumors carrying BRAF-mutations over-express NAMPT that is genetically amplified and possesses oncogenic properties.
Audrito V; Moiso E; Ugolini F; Messana VG; Brandimarte L; Manfredonia I; Bianchi S; De Logu F; Nassini R; Szumera-Ciećkiewicz A; Taverna D; Massi D; Deaglio S
J Transl Med; 2022 Mar; 20(1):118. PubMed ID: 35272691
[TBL] [Abstract][Full Text] [Related]
3. RICTOR/mTORC2 downregulation in BRAF
Ponzone L; Audrito V; Landi C; Moiso E; Levra Levron C; Ferrua S; Savino A; Vitale N; Gasparrini M; Avalle L; Vantaggiato L; Shaba E; Tassone B; Saoncella S; Orso F; Viavattene D; Marina E; Fiorilla I; Burrone G; Abili Y; Altruda F; Bini L; Deaglio S; Defilippi P; Menga A; Poli V; Porporato PE; Provero P; Raffaelli N; Riganti C; Taverna D; Cavallo F; Calautti E
Mol Cancer; 2024 May; 23(1):105. PubMed ID: 38755661
[TBL] [Abstract][Full Text] [Related]
4. Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT).
Audrito V; Managò A; Gaudino F; Deaglio S
Semin Cell Dev Biol; 2020 Feb; 98():192-201. PubMed ID: 31059816
[TBL] [Abstract][Full Text] [Related]
5. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
Zhu G; Yi X; Haferkamp S; Hesbacher S; Li C; Goebeler M; Gao T; Houben R; Schrama D
Cancer Lett; 2016 Jun; 376(1):43-52. PubMed ID: 27000992
[TBL] [Abstract][Full Text] [Related]
6. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
7. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
Gallagher SJ; Gunatilake D; Beaumont KA; Sharp DM; Tiffen JC; Heinemann A; Weninger W; Haass NK; Wilmott JS; Madore J; Ferguson PM; Rizos H; Hersey P
Int J Cancer; 2018 May; 142(9):1926-1937. PubMed ID: 29210065
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
9. NAD
Moore AM; Zhou L; Cui J; Li L; Wu N; Yu A; Poddar S; Liang K; Abt ER; Kim S; Ghukasyan R; Khachatourian N; Pagano K; Elliott I; Dann AM; Riahi R; Le T; Dawson DW; Radu CG; Donahue TR
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33597293
[TBL] [Abstract][Full Text] [Related]
10. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
[TBL] [Abstract][Full Text] [Related]
13. Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma.
Corre S; Tardif N; Mouchet N; Leclair HM; Boussemart L; Gautron A; Bachelot L; Perrot A; Soshilov A; Rogiers A; Rambow F; Dumontet E; Tarte K; Bessede A; Guillemin GJ; Marine JC; Denison MS; Gilot D; Galibert MD
Nat Commun; 2018 Nov; 9(1):4775. PubMed ID: 30429474
[TBL] [Abstract][Full Text] [Related]
14. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
Fratangelo F; Camerlingo R; Carriero MV; Pirozzi G; Palmieri G; Gentilcore G; Ragone C; Minopoli M; Ascierto PA; Motti ML
Int J Oncol; 2018 Sep; 53(3):1149-1159. PubMed ID: 29956724
[TBL] [Abstract][Full Text] [Related]
15. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.
Ohanna M; Cerezo M; Nottet N; Bille K; Didier R; Beranger G; Mograbi B; Rocchi S; Yvan-Charvet L; Ballotti R; Bertolotto C
Genes Dev; 2018 Mar; 32(5-6):448-461. PubMed ID: 29567766
[TBL] [Abstract][Full Text] [Related]
16. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
17. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
Liu S; Tetzlaff MT; Wang T; Yang R; Xie L; Zhang G; Krepler C; Xiao M; Beqiri M; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Xu W; Wei Z; Herlyn M; Yao Y; Zhang L; Wang Y; Zhang L; Xu X
Pigment Cell Melanoma Res; 2015 Jul; 28(4):431-41. PubMed ID: 25903073
[TBL] [Abstract][Full Text] [Related]
18. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
[TBL] [Abstract][Full Text] [Related]
19. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
20. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
[No Abstract] [Full Text] [Related]
[Next] [New Search]
